Altimmune, Inc. - 8-K Filing
Altimmune reported $332 million in cash, cash equivalents, and short-term investments as of March 31, 2026, which increased to approximately $535 million by April 30 due to a recent public offering. The company plans to initiate its PERFORMA Phase 3 MASH trial in the second half of 2026 after receiving Breakthrough Therapy Designation from the FDA for pemvidutide based on IMPACT Phase 2b data. (Items: 2.02 Results of Operations and Financial ConditionOn May 13, 2026, Altimmune, Inc, 9.01 Financial Statements and Exhibits(d) ExhibitsNo)
Tickers: $ALT